Adipotide vs Semaglutide
Emerging vs FDA Approved
monitor Researched · 90% Potential additive dehydration/GI effects; monitor renal function.
Molecular Data
Adipotide Semaglutide
Weight N/A 4,113.64 Da
Half-life Not established ~7 days (168 hours)
Chain N/A 31 amino acids
Type Chimeric peptidomimetic GLP-1 receptor agonist
Key Benefits
Adipotide
01 Rapid fat-mass reduction via selective white adipose tissue vascular targeting
02 Improved insulin sensitivity following adipose reduction
03 Non-CNS peripheral mechanism distinct from appetite suppressants
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
Adipotide
0.43 mg/kg / Once daily
Primate Research Replication 0.43 mg/kg Once daily
Dose-Finding (Research) 0.10-0.75 mg/kg Once daily (escalating tiers)
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
Adipotide
Mild creatinine elevation
Electrolyte shifts
Dose-dependent proximal tubule changes (reversible in primates)
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Pregnancy/lactation (not studied)
Dehydration
Concurrent nephrotoxic medications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Adipotide Semaglutide
Status Emerging FDA Approved
References 4 studies 9 studies
Latest — 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.